🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Egypt / NCT07780760
Recruiting Not applicable

Effect of Preoprative Nebulized Dexmedetomidine Compared to Nebulized Lidocaine in Attenuating Sore Throat Following Tonsillectomy In Childern.

NCT07780760 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-09-01
Last updated
2026-08-21

Condition(s) studied

Sore ThroatDexmedetomidine AnalgesiaTonsillectomy

Investigational drug(s) / intervention(s)

Group D (dexmedetomidine group)Group L (Lidocaine group)

Group D (dexmedetomidine group): group D (Dexmedetomidine group) will recieve a dose of 1 mcg/kg

Group L (Lidocaine group): will recieve Lidocaine 2%, 1 mg/kg

Study summary

The aim of the study is to compare the effect of nebulized Dexmedetomidine compared to nebulized Lidocaine on postoperative sore throat in childern undergoing Tonsillectomy.

Eligibility

Sex
FEMALE
Min age
3 Years
Max age
15 Years
Healthy volunteers
No
Inclusion Criteria: * Age: Childern between 3:15 years old * American Society of Anesthesiologists(ASA) Physical Status I or II * Elective Tonsillectomy Exclusion Criteria: * Parents refusal * Presence of preoperative sore throat * Known allergy to the study drug * History of upper respiratory tract infection 2 weeks prior to surgery * Mental retardation or inability to communicate * Significant Cardiovascular disease as Heart Block * Post Tonsillectomy bleeding

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Fayoum university Hospitl Al Fayyum Egypt Recruiting

More Fayoum University Hospital trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07780760 on ClinicalTrials.gov ↗ ← All trials in Egypt